期刊文献+

Ⅲ期非小细胞肺癌放射治疗射野累及器官的放射损伤研究 被引量:2

Clinical study of irradiation-induced injury of organs at risk in radiotherapy of Stage Ⅲnon-small cell lung cancer
下载PDF
导出
摘要 目的:探讨Ⅲ期非小细胞肺癌(nonsmall cell lung cancer,NSCLC)适形放射治疗中累及野照射组(involved—field irradiation,IFI组)提高靶区剂量的同时,放射损伤是否高于预防照射组(elective node irradiation,ENI组)。方法:将200例Ⅲ期NSCLC患者随机分为IFI组和ENI组,IFI组处方量为68~74Gy/34~37次,ENI组为60-64Gy/30-32次,比较两组的近期疗效和放射损伤。结果:IFI组和ENI组的CR率分别是35%和27%,其差异无统计学意义,X^2=1.50,P=0.23;但总有效(CR4-PR)率分别是90%和79%,其差异有统计学意义,X^2=4.62,P=0.03。IFI组骨髓抑制和心脏损伤低于ENI组,但差异无统计学意义,P值分别为0.14和0.52;IFI组和ENI组放射性食管炎发生率相同(1~2级和3级的P值分别为0.59和0.71);IFI组和ENI组急性放射性肺炎发生率分别为17%和29%,差异有统计学意义,X^2=4.06,P=0.04。根据剂量体积直方图(dose-volume histogram,DVH)分析,全肺接受≥20Gy的体积(V20)与放射性肺炎发生率的关系如下:V20<20%者为10.8%(13/120),V20为20%~25%者为32.1%(17/53),V20为25%~30%者为52.3%(11/21),V20≥30%者为83.3%(5/6)。结论:IFI治疗Ⅲ期NSCLC,患者耐受性好,总有效率高于ENI组,放射损伤发生率并未增加,放射性肺炎的发生率低于ENI组,即IFI提高靶区照射剂量的同时不增加放射损伤,有望提高患者的长期生存率。 OBJECTIVE:To explore the incidence of irradiation-induced injury while the involved-field irradiation (IFI) increased the target doses in stage Ⅲ non-small cell lung cancer (NSCLC). METHODS: From September 1997 to November 2001, 200 patients with stage-Ⅲ NSCLC were randomized into two groups-IFI and ENI (elective node irradiation). The IFI group were irradiated by 68-74 Gy/34-37 f. The ENI group were irradiated by 60-64 Gy/30-32 f. The short-time curative effect and the irradiation-induced injury were compared. RESULTS: The CR rates were 35% and 27% in IFI group and ENI group, respectively, and there was no significance, χ~2=1.50,P=0.23, while the overall response (CR+PR) rates were 90% and 79%, χ~2=4.62,P=0.03. Bone marrow depression and radiation-induced heart damage were lower in IFI group than in ENI group, but there were no significance, P values were 0.14 and 0.52. Radiation esophagitis incidence were the same in IFI and ENI groups (1-2 grade and 3 grade’s P value were 0.59 and 0.71). Radiation-induced pneumonitis occurred in 17% of patients in IFI and 29% in ENI, respectively. The difference were significant, χ~2=4.06,P=0.04. The relation between the lung volume receiving≥20 Gy(V_(20)) and the incidence of radiation-induced pneumonitis as the basis of Dose-volume Histogram(DVH)were as follows: while V_(20)<20%, the radiation-induced pneumonitis incidence was 10.8%(13/120); V_(20) ranged from 20% to 25%, it was 32.1%(17/53); V_(20) between 25% and 30%, 52.3%(11/21); V_(20)≥30%, 83.3%(5/6), respectively. CONCLUSIONS: IFI for the patients of Stage-Ⅲ NSCLC is well tolerated. The overall response rate is higher than in ENI. The incidence of irradiation-induced injury is not increased, while the radiation-induced pneumonitis is lower in IFI than in ENI. That is to say, IFI elevates the target doses but does not increase the irradiation-induced injury, thus would improve the survival.
出处 《肿瘤防治杂志》 2005年第10期772-775,共4页 China Journal of Cancer Prevention and Treatment
关键词 非小细胞肺/放射疗法 累及野 放射损伤 回顾性研究 carcinoma, non-small cell lung /radiotherapy involved-field irradiation irradiation-induced injury retrospective studies
  • 相关文献

参考文献9

  • 1黎庶,马述盛,王天君,张景荣,赵惠儒,傅志民.CT诊断肺癌纵隔淋巴结转移判定标准的研究[J].中国医科大学学报,1995,24(2):193-195. 被引量:2
  • 2于金明,郭守芳,李万湖,黄勇,尹莉萍,付政,李文武.非小细胞肺癌术前肺门纵隔淋巴结CT检查和术后病理结果比较的研究[J].肿瘤防治杂志,2003,10(12):1287-1289. 被引量:11
  • 3Cox J D , Stetz J , Paiak T F. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC)[J]. Int J Radiat Oncol Biol Phys, 1995,31(5):1341-1346.
  • 4WHO handbook for reporting results of cancer treatment[M]. Offset Publication No. 48. Geneva( Switzerland): World Health Organization, 1979.
  • 5Belderbos J S, Jaeger K D, Heemsbergen W D, et al. First resuits of a phase Ⅰ/Ⅱ dose escalation trial in non-small cell lung cancer using three-dimensional conformal radiotherapy[J]. Radiother Oncol, 2003,66(2):119-126.
  • 6Senan S, Burgers S, Samson M J, et al. Can elective nodal irradiation be omitted in stage Ⅲ non-small cell lung cancer? Analysis of recurrences in a phase Ⅱ study of induction chemotherapy and involved field radiotherapy [J]. Int J Radian Oncol Biol Phys,2002,54(4):999-1006.
  • 7Tsuiino K, Hirota S, Endo M, et al. Predictive value of dosevolume histogram parameters for predicting radiation pneumonitis after concurrent chemoradiation for lung cancer[J]. Int J Radiat Oncol Biol Phys, 2003,55(1):110-115.
  • 8Hirota S, Tsujino K, Endo M, et al. Dosimetric predictors of radiation esophagitis in patients treated for non-small cell lung cancer with carboplatin/paclitaxel/radiotherapy[J]. Int J Radiat Oncol Biol Phys,2001,51(2):291-295.
  • 9Rosenman J G, Halle J S, Socinski M A, et al. High-dose conformal radiotherapy for treatment of stage Ⅲ a/Ⅲ b non-small cell lung cancer: technical issues and results of a phase Ⅰ/Ⅱ trial[J]. Int J Radiat Oncol Biol Phys,2002,54(2):348-356.

二级参考文献12

  • 1团体著者,肺癌,1980年,20卷,433页
  • 2Raeter TP,Hellwig D,Hoffmann K,et al. Mediastinal lymph node staging in suspected lung cancer: comparison of positron emission tomography with F-18-fluorodeoxyglucose and mediastinoscopy[J].Ann Thorac Surg, 2003,75(1):231-235.
  • 3Gupta NC,Tamim WJ,Graeber GG. Mediastinal lymph node sampling following positron emission tomography with fluorodeoxyglucose imaging in lung cancer staging[J].Chest,2001,120(2):521-527.
  • 4Roman MR,Rossleigh MA,Angelides S,et al. Staging and managing lung tumor using F-18 FDG coincidence detection[J].Clin Nucl Med,2001,26(5):383-388.
  • 5Fritscher RA,Bohuslavizki KH,Brandt L,et al. Mediastinal lymph node involvement in potentially resectable lung cancer:comparison of CT,positron emission tomography,and endoscopic ultrasonography with and without fine-needle aspiration[J].Chest,2003,123(2):442-451.
  • 6Imdahl A,Jenkner S,Brink I,et al. Validation of FDG positron emission tomography for differentiation of unknown pulmonary lesions[ J].Eur J Cardiothorac Surg,2001,20(2):324-329.
  • 7Eschmann SM,Friedel G,Paulsen F,et al. FDG-PET for staging of advanced non-small cell lung cancer prior to neoadjuvant radio-chemotherapy[J].Eur J Nucl Med Mol Imaging,2002,29(6):804-808.
  • 8Vonhaag DW,Follette DM,Roberts PF,et al. Advantages of positron emission tomography over computed tomography in mediastinal staging of non-small cell lung cancer[J].J Surg Res,2002,103(2):160-164.
  • 9Damico TA,Wong TZ,Harpole DH,et al. Impact of computed tomography-positron emission tomography fusion in staging patients with thoracic malignan cies[J].Ann Thorac Surg,2002,74(1):160-163.
  • 10Magnani P,Carretta A,Rizzo G,et al. FDG-PET and spiral CT image fusion for medistinal lymph node assessment of non-small cell lung cancer patients[J].J Cardiovasc Surg,1999,40(5):741-748.

共引文献10

同被引文献8

  • 1Yoshino I,Yamaguchil M, Yokamotu T, et al. Muhimodal treatment for resectable epithelial type malignant pleural mesothelioma [J]. World Journal of Surgical Oncology ,2004,2 ( 5 ) : 11.
  • 2Sugarbaker DJ,Flores R,Jaklitsch MT, et al. Resection margins, extrapleural nodal status, and ceil type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: Results in 183 patients [ J]. J Thorac Cardiovasc Surg, 1999,117(1) :54 -65.
  • 3Rusch VW, Rosenzweig K,Venkatraman E, et al. A phase Ⅱ trial of surgical resection and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma [ J ]. Thorac Cardiovasc Surg, 2001, 122(4):788-795.
  • 4Ahamad A, Stevens CW, Smythe WR, et at. Intensity-modulated radiation therapy: A novel approach to the management of malignant pleural mesothelioma [ J ]. lnt J Radiat Oncol Biol Phys,2003,55 (3) :768 - 775.
  • 5Allen AM, Czerminska M, Janne PA, et al. Fatal pneomonitis associated with intensity-modulated radiation therapy for mesothelioma[ J ]. lnt J Radiat Oncol Biol Phys, 2006, 65 (3):640 - 645.
  • 6Bottomley A,Gaafar R,Manegold C, et al. Short-term treatment- related symptoms and quality of life: Results from an international randomized phase Ⅲ study of eisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: An EORTC Lung-Cancer Group and National Cancer Institute, Canada, Intergroup study[J1. J Clin Oneol, 2006, 24(9):1435 -1442.
  • 7Ceresoli GL,Gridelli C, Santoro A. Muhidisciplinary Treatment of Malignant Pleural Mesothelioma [ J ]. Oncologist, 2007, 12 (7) :850 -863.
  • 8Weder W,Kestenholz P,Taverna C, et al. Neoadjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma [ J ]. J Clin Oocol, 2004,22 ( 17 ) : 3451 - 3457.

引证文献2

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部